HEMPFUSION WELLNESS INC - CBDHF STOCK NEWS

HempFusion Wellness (“the Company”) has filed its annual and fourth quarter results for the fiscal year ending December 31, 2020. The Company distributes its brands to around 4,000 retail locations across the U.S. and select international markets. HempFusion boasts a product portfolio of 48 SKUs and has 30 additional products in development. The Company is recognized for its focus on regulatory compliance and research-driven product development and is a member of the US Hemp Roundtable.

HempFusion Wellness Inc. (TSX:CBD.U) announced the completion of a pilot study with the Inflammatory Markers Laboratory, demonstrating that its CBD Capsules® may significantly reduce thromboxane production, a marker linked to inflammation. The results indicate potential benefits in managing chronic inflammation and have led to the creation of a white paper titled “Oral Formulation May Modulate Thromboxane Production.” The study, co-authored by notable experts, reflects HempFusion's commitment to research in hemp-derived CBD and its safe, effective applications. The company also sponsors one of the largest CBD toxicology studies.

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) announced initial findings from a large observational liver toxicology study on hemp-derived CBD products. Conducted by Validcare, the study showed no evidence of liver toxicity among the 839 participants. The FDA was briefed on these findings, which aim to inform safe regulatory pathways for CBD products. The study's success has led to the addition of a second cohort for increased statistical certainty. The results are seen as a pivotal step forward for the CBD industry, validating HempFusion's commitment to consumer safety.

HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) announces the launch of Probulin products on Alibaba's Tmall Global, expanding its market reach to over 750 million consumers in Asia. The expected availability starts March 29, 2021, coinciding with the significant 618 shopping festival in China, which saw USD$98.52 billion in sales last year. This marks a pivotal moment in HempFusion’s growth strategy, as it aims to leverage Tmall’s vast consumer engagement opportunities, including influencer marketing, to educate the market about its probiotic benefits.

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) announces its OTC Topical Products have achieved the highest rank in sales dollars and units sold at a major Food & Drug Mass retailer, as reported by NielsenIQ. This milestone reflects the company’s commitment to regulatory compliance and high-quality product development. The Food & Drug Mass channel is identified as a key growth opportunity, with an anticipated increase in consumer purchasing of CBD products. HempFusion aims to expand its distribution across additional major retailers in the U.S. and globally.

HempFusion Wellness has submitted a novel foods application to the UK's Regulatory Food Safety Agency (FSA) as part of the regulatory approval process for CBD products. This comprehensive submission includes toxicology data and details on the quality and safety of HempFusion's ingredients. The application is seen as essential to the company's growth in the UK market and in anticipation of EU regulations. HempFusion emphasizes its commitment to regulatory compliance and consumer safety through ongoing studies, including participation in ValidCare’s significant human observational study.

HempFusion Wellness Inc. (TSX:CBD.U, OTCQX:CBDHF) announced its common shares received DTC full-service eligibility, allowing trading through DTC's electronic system in the U.S. This approval will enhance liquidity and attract a broader range of investors, including online trading platforms and brokerage firms. The company's product portfolio includes 48 SKUs of CBD products and 30 additional products under development.

HempFusion Wellness announced its exclusive CBD brand selection by Mount Sinai Medical Hospital for a six-month clinical trial. Conducted by Dr. David Harnick, this trial aims to evaluate CBD's impact on cardiology markers and deepen understanding of its effects. Commencing in March 2021, it represents significant research in CBD's health benefits, as no prior controlled studies exist on this topic. HempFusion’s CBD products will also be part of the ValidCare observational studies focused on liver and reproductive health.

HempFusion Wellness has expanded its product line to 48 SKUs with new Sleep and Stress products featuring twice the CBD per serving, now at 300 mg. The company aims to cater to the increasing demand for higher CBD concentrations among consumers. The products, containing GABA and ASHWAGANDHA, are designed to support relaxation and ease stress while remaining THC-free. Available on their website, these innovations reflect HempFusion's commitment to providing sought-after health solutions in the CBD market.